Skip to main content

Advertisement

Table 1 Main baseline characteristics of HCV monoinfected and HIV-HCV coinfected patients (n = 86)

From: Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients

Characteristics HCV (n = 63) HIV-HCV (n = 23) p value
Gender ratio (M/F) 2.0 6.7 0.063
Age (years) 50 (23–74) 46 (35–60) 0.066
Body weight (kg) 75 (41–130) 69 (52–96) 0.032
Men body weight (kg) 79 (44–130) 69 (52–96) 0.008
Body mass index (BMI) 25.7 (16.4-43.3) 22.1 (17.6-32.8) 0.003
Men body mass index (BMI) 25.8 (18.4-43.3) 22.2 (17.6-32.8) 0.002
Creatinine (μmol/L) 76 (49–189) 82 (45–123) 0.164
Cockroft clearance (mL/min) 105.7 (44–257.7) 90.2 (67.2-202.9) 0.244
MDRD (mL/min) 90.9 (34.2-167.5) 89.5 (58.2-144.7) 0.880
ALT (IU/mL) 62 (20–383) 60.5 (20–1492) 0.853
AST (IU/mL) 47 (20–402) 57 (26–969) 0.485
HCV RNA (log IU/mL) 6.1 (3.59-6.99) 6.4 (2.81-7.39) 0.111
Hemoglobin level (g/dl) 14.5 (8.2-17.2) 15.2 (12.1-18.8) 0.036
Men hemoglobin level (g/dl) 15 (8.3-17.2) 15.2 (12.1-18.8) 0.239
HCV genotype n (%)    0.566
1 48 (76) 14 (61)  
2 2 (3) 1 (4)  
3 6 (10) 4 (17)  
4 7 (11) 4 (17)  
Fibrosis score (Metavir) n (%)    0.780
0 – 2 29 (46) 12 (52)  
3 – 4 34 (54) 11 (48)  
HCV treatment status at baseline n (%)    0.434
HCV treatment naive 19 (30) 9 (41)  
Nonresponders 25 (40) 9 (41)  
Relapsers 19 (30) 4 (18)  
  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; MDRD, Modification of the Diet in Renal Disease. Bold style indicates statistical significance. Quantitative variables are expressed as median and range.